They concluded that TET2 was a novel bona fide tumor suppressor, noting that the majority of mutations are heterozygous (55%) and that TET2 defects precede the well-known JAK2 V617F driver mutation in MPN HSCs (Delhommeau et al., 2009). This evidence concerns the gene JAK2 and myeloproliferative disorder.